Abstract

Objective:To evaluate the efficacy and toxicity of methotrexate (MTX) monotherapy compared with MTX combination with non-biological disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis.Method:A systematic review of randomised trials...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
Judith Trudeau ... Wanruchada Katchamart
The Cochrane database of systematic reviews | VOL. 2015
Judith Trudeau, et. al.Judith Trudeau ... Wanruchada Katchamart
14 Apr 2010
AB0424 Rheumatoid Arthritis Patients Receiving Biological Therapy in Colombia. Survey of Compliance and Causes of Methotrexate Suspension
G Marianella ... D Aura
Annals of the Rheumatic Diseases | VOL. 73
G Marianella, et. al.G Marianella ... D Aura
01 Jun 2014
EP14 Association between initial csDMARD strategy and disease activity at 6 months in patients with new onset rheumatoid arthritis
Douglas Steinke ... Suzanne Verstappen
Rheumatology | VOL. 59
Douglas Steinke, et. al.Douglas Steinke ... Suzanne Verstappen
01 Apr 2020
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice
Hisashi Baba ... Richio Fukai
Modern Rheumatology | VOL. 25
Hisashi Baba, et. al.Hisashi Baba ... Richio Fukai
01 Jul 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers